VNDA
Vanda Pharmaceuticals Inc.
Key Financials
Operating Income
$-151168000
↓ 271.8%
Revenue
$216.1M
↑ 8.7%
Net Income
$-220474000
↓ 1066.5%
Gross Profit
$60.9M
↑ 12.6%
EPS (Diluted)
$-3.74
↓ 1033.3%
Cash & Equivalents
$84.9M
↓ 17.1%
Total Liabilities
$161.8M
↑ 37.5%
Total Assets
$488.9M
↓ 25.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/13/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VNDA |
| Company Name | Vanda Pharmaceuticals Inc. |
| CIK | 1347178 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 202-734-3400 |